Business Wire

CA-BELKIN

4.1.2023 15:01:52 CET | Business Wire | Press release

Share
Belkin celebrates 40 years of industry leadership by introducing a more responsible way to build products

Belkin, a global consumer electronics leader, after two years of development, today introduces a new product material refresh for its top selling mobile power products. Several of Belkin’s most popular wireless chargers, power banks, wall chargers, and car chargers will receive updated product housing materials that consist of 73-75% post-consumer recycled plastics (PCR) and plastic-free packaging. The product transition will be rolled out beginning 2023 and will save an estimated 7,000 metric tons of carbon emissions1 and reduce CO2-eq emissions for these products by up to 67%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230104005370/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

The company celebrates 40 years as a market leader and innovator by honoring its deeply rooted commitment to sustainability. Belkin is already on its way to becoming 100% carbon neutral in scope 1 & 2 emissions by 2025. Its commitment to reviewing all areas of the business has included a focus on reducing single-use plastics in packaging which has seen up to a 90% reduction in plastic usage in some products. Today’s announcement addresses Belkin’s approach to reducing its scope 3 emissions.

Belkin made a deliberate and methodical decision to transition product materials to PCR. This takes plastic waste from consumers and repurposes it to create new products. It utilizes plastic that is destined for landfill, giving it new life, while taking meaningful steps to support the circular economy by reducing dependence on virgin plastics. The Life Cycle Assessment conducted by the company shows that utilizing PCR material has a significant reduction in environmental impact.

There are other plastic alternatives in the industry such as:

  • Recycled plastic (PIR), a method that reuses plastic materials collected at a factory during mass production
  • Bioplastics, which uses materials from renewable feedstocks such as plants and woodchips
  • Ocean plastics, which reuses plastic waste collected from the ocean

“When we think about the difference a company of our size and influence can make on the planet, moving away from using virgin plastics in our products is an obvious decision,” said Steve Malony, CEO, Belkin. “I am proud to work alongside the teams that made this shared vision a reality. Their dedication to doing the right thing inspires me and together, we will continue to work towards a more sustainable future.”

The following products will be the first to ship with the new PCR material throughout 2023:

From an aesthetic, quality and engineering perspective, there will be little difference between existing Belkin products and Belkin PCR products. Consumers will be able to decipher the new PCR products by clear callouts on the packaging and product pages online such as: “Made with Recycled Plastic Products” and “100% Plastic Free Packaging.”

Belkin’s engineering and product development teams are based in Los Angeles, Hong Kong, Shenzhen, Vietnam and Taiwan, and work tirelessly to develop innovation that changes the way people connect with their technology while reducing impact on the planet. Belkin takes quality seriously, and nothing enters the market until rigorous testing and approval processes take place. For this new PCR portfolio, Belkin additionally continues to explore new solutions and to conscientiously verify the science behind how Belkin can further reduce its impact on the planet while not compromising on quality. PCR material was sourced from reputable resin vendors and selected and tested by Belkin’s design assurance team.

To learn more about Belkin Sustainability, visit: https://www.belkin.com/company/sustainability/

Press kit can be found here.

About Belkin

Belkin is an accessories market leader delivering power, protection, productivity, connectivity, audio, security, and home automation solutions for a broad range of consumer electronics and enterprise environments. Designed in Southern California and sold in more than 50 countries around the world, Belkin creates products that empower people to get more life out of every single day whether at home, at work or on a new adventure. In 2018 Belkin International merged with Foxconn Interconnect Technology to bolster its global influence and remain forever inspired by people and the planet we live on.

1 Based on forecasted calculations from May 2022

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230104005370/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye